Compare Inovio Pharmaceuticals Inc (INO) vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $69.36. The key difference: Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SLVO | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $2.87 | $107.41 |
52-Week Low | $0.66 | $61.81 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
SLVO trades at $69.28, showing modest daily gains of 0.35%. Technical indicators present a mixed picture with a bullish moving average signal but bearish oscillators, including an overbought RSI. Recent news highlights volatility, with the stock crossing below its 50-day moving average last week. Fundamental data is unavailable in the provided snapshot, requiring further review of SEC filings for financial health assessment.
The outlook is cautious due to conflicting technical signals and lack of current fundamental metrics. Investment opportunity hinges on silver price trends and covered call strategy performance, but risks include commodity volatility and dollar strength impacting silver, as noted in recent financial news. Investors should seek updated financials for a complete view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →
